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A B S T R A C T
Background
The provision of preconception counselling to women with epilepsy (WWE) has become established as recommended practice and
includes a review of drug treatment and the provision of information and advice on both seizure and treatment-related risks to both
mother and child. In this review we assess the evidence regarding the effectiveness of preconception counselling for WWE.
Objectives
To determine the effectiveness of preconception counselling for WWE, measured by a reduction in adverse pregnancy outcome in both
mother and child; increased knowledge of preconception issues in WWE and increasing intention to plan pregnancy.
Search strategy
We searched the Epilepsy Group’s Specialized Register (30/01/2008), the Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library 2007, Issue 4), and electronic databases: MEDLINE (OVID) (1950-February 2008); SCOPUS (1966-March
2008); CINAHL (1982-March 2008); PsyclNFO (1806-March 2008); ASSIA (1987-March 2008).
Selection criteria
Randomised control trials; including cluster and quasi-randomised trials, prospective cohorts, controlled before and after studies, and
interrupted time series that compared the outcomes in mothers with epilepsy and infants of mothers with epilepsy who received
preconception counselling, to the outcomes of mothers with epilepsy and their infants who received standard care or no intervention.
Data collection and analysis
The methodological quality of potentially relevant studies were assessed to determine appropriate inclusion. Where necessary, study
authors were contacted for additional information. No studies met the review inclusion criteria.
Main results
The search strategy identified 11 studies for consideration of inclusion. However, none met the required criteria for inclusion.
Authors’ conclusions
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There is no evidence to inform the content, methods of delivery or effectiveness of preconception counselling to improve pregnancy
outcomes forWWE and their offspring. The value of counselling delivered toWWEprior to conception, with the intention of reducing
the risks of adverse outcome in mother and child, requires evaluation in well-designed studies, appropriately powered to detect changes
in both maternal and infant outcome.
P L A I N L A N G U A G E S U M M A R Y
Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome
No evidence to support preconception counselling for women with epilepsy.
The majority of women with epilepsy will experience a normal pregnancy and delivery; however, this requires informed decisions by
women, balancing the risk to the fetus against the need to maintain seizure control during their reproductive years. The review did not
find any evaluations of preconception counselling and educational interventions that were of sufficient quality to be included in the
systematic review. There was not enough evidence to reach a conclusion about the effect of counselling and educational interventions
to improve pregnancy outcome for women with epilepsy preparing for pregnancy.
2Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
B A C K G R O U N D
Epilepsy is the most common serious neurological disorder, with
a worldwide incidence varying between 40 and 80 per 100,000
people (Wallace 1998), and a lifetime prevalence of developing
an active epilepsy in the UK of 4/1000 population (MacDonald
2002). The incidence of a treated epilepsy in the UK, calculated
by the UK General Practice Research Database (GPRD), was es-
timated at 80.8 per 100,000 people (Wallace 1998), and an age-
specific prevalence rate in treated women with epilepsy aged 16-
44 years of between 6.9 and 7.8 per 1000 (Purcell 2002).
Women with epilepsy (WWE) during their child-bearing years
face specific gender-based challenges relating to their experience
of epilepsy and its treatment: namely, the potential for changes in
menstrual function and fertility, interaction with hormonal con-
traception and the potential risk for adverse pregnancy outcome
as a result of the teratogenic effects of antiepileptic drugs (AEDs)
upon the developing fetus (Morrell 1998; Stokes 2004).
The outcome of pregnancy for most WWE is normal; however,
there are additional risk factors for the mother and child includ-
ing: potential teratogenic effects of AEDs; potential effect of ma-
ternal seizures on the developing fetus, and genetic risks, all of
which contribute to a two- to three-fold increased risk of adverse
outcome (Barrett 2003). The potential risk of adverse pregnancy
outcome includes the risk for maternal mortality and morbidity,
and the risk of fetal major congenital malformation (MCM) and
long-term developmental delay. Although not all women would
require ongoing treatment, recent estimates suggest around 95%
of WWE remain on treatment in the US, resulting in approxi-
mately 22,800 children born each year following in-utero AED
exposure (Meador 2004). Potential adverse pregnancy outcome
due to AED exposure resulting in birth defect and delayed de-
velopment has been recognised in several large prospective cohort
studies and registries; however, methodological shortcomings, in-
cluding insufficient sample size, have led to uncertainties about the
precise risks (Adab 2004a), especially for the newer antiepileptic
drugs (Adab 2001; Adab 2004; Kini 2006; Morrow 2006; Vinten
2004). The UK Epilepsy and Pregnancy Register confirmed that
the risk for MCM was significantly higher for infants exposed to
multiple, rather than single, antiepileptic drug regimes. The crude
rate for MCM with any polytherapy exposure was 6.0% (adjusted
odds ratio (OR) 1.76; 95% confidence interval (CI) 0.80 to 3.86),
compared to 3.7% (adjusted OR 1.03; 95% CI 0.49 to 2.17) for
pregnancies exposed to a single antiepileptic drug; with 95% CI
calculated using no AED exposure as comparator, adjusting for
age at delivery, parity, family history of MCM, periconceptional
folic acid exposure and sex of infant (Morrow 2006). Increasing
evidence of a drug-specific risk of adverse pregnancy outcome has
been demonstrated from several recent studies, with Valproate
posing the highest risk to the fetus (Meador 2006; Vajda 2006;
Wyszynski 2005). While caution is required in interpreting the
findings of these observational studies, the potential drug-specific
risk has directed clinical practice guidelines recommending avoid-
ance or reduction of the dosage of sodium valproate ahead of con-
ception where possible (Tomson 2007).
The potential risks from AED treatment must be balanced against
the potential risk from seizures during pregnancy; with concern
for the impact of maternal tonic-clonic seizures during pregnancy
upon fetal development (Adab 2004). Reports from a commu-
nity-based Finnish study and the EURAP study group have sug-
gested that there maybe a relatively low risk of changes in seizure
frequency during pregnancy, with 56% of women reporting no
change in seizure frequency and 58.3% remaining seizure free
throughout their pregnancies (EURAP 2006; Viinikainen 2006).
Measures of seizure frequency from observational studies need to
account for the potential influence of confounding factors and the
ability of the findings to represent the population of WWE, sup-
ported by the less encouraging report within the same publication
that status epilepticus occurred in 1.8% of pregnancies (EURAP
2006). The UK Confidential Enquiry into Maternal Deaths iden-
tifiedWWE at an indirect risk of mortality, reporting 11 epilepsy-
related deaths from 2003 to 2005, six meeting the criteria for sud-
den unexpected death in epilepsy (SUDEP), and a further two
late deaths meeting the criteria for SUDEP (late deaths defined as
occurring between 42 days and one year after abortion, miscar-
riage, or delivery that are due to direct or indirect maternal cause)
(CEMACH 2007). A consistent recommendation throughout all
recent CEMACH reports has been the need to establish epilepsy
review mechanisms that promote increased awareness and knowl-
edge both about epilepsy management prior to and during preg-
nancy, while promoting the need for WWE, their partners and
family to engage with epilepsy review services. The report draws
attention to the uncertainty of association between SUDEP and
pregnancy, concluding that pregnancy is an indirect risk factor
for SUDEP as many women stop treatment through reluctance
when pregnant or breastfeeding for fear of harming the baby (
CEMACH 2007). Promoting increased awareness of the impor-
tance of seizure control in WWE and the role AEDs play in main-
taining seizure control is seen as a component of preconception
counselling (Kalviainen 2006).
Preconception counselling is a complex intervention; built up from
a number of components, including behavioural parameters and
organisational issues of timing and delivery, all contributing to
difficulties in defining the ’active ingredients’ of the intervention
(MRC 2000). It has been defined as the process of planning and
preparation for pregnancy, through which physical, mental and
emotional health is optimised ahead of conception (Chamberlain
1986). As a complex intervention, it brings together an interven-
tional process involving assessment, planning, treatment, educa-
tion, decision support and counselling, resulting in a wide range
of potential health outcomes before, during and after pregnancy
for both the woman and her future offspring.
The components of preconception counselling for WWE incor-
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porate family planning and promote the use of contraception, to
delay pregnancy by influencing the time and spacing of pregnancy
to ensure optimal maternal health prior to conception (Klerman
2006). This requires an ongoing process of preparation and review
of epilepsy management, to ensure the woman conceives with a
minimum of risk factors, is fully aware of any risks and benefits
of treatment, and is able to make informed decisions about future
pregnancies (Crawford 2005). For many WWE, their plans for
pregnancy may not be explicit, with more than 50% of UK preg-
nancies in WWE unplanned (Fairgrieve 2000), emphasising the
need for information provision throughout reproductive age, and
reinforcing the importance of contraceptive advice as a precon-
ception counselling intervention to reduce unplanned pregnancy.
An essential component of preconception counselling relies on the
provision of information to enable women to make informed de-
cisions. This must take account that concern for both epilepsy and
AED therapy can influence decisions made by women regarding
pregnancy; with WWE reported as more likely than their health-
care providers to initiate conversations about pregnancy issues (
Vazquez 2007). However, WWE appear to experience difficulty
recalling the provision of information about preconception issues
(Bell 2002; Crawford 2003; Wallace 1999); only 38% of women
in a UK prospective population-based study of the care of women
with epilepsy in pregnancy recalled receipt of preconception coun-
selling (Fairgrieve 2000); and a quarter of surveyed female mem-
bers of the British Epilepsy Association did not discuss pregnancy
with anyone (Crawford 1999a).
The need to take account of a failure to access healthcare systems
by WWE, either when planning pregnancy or on discovery of an
unplanned pregnancy, was emphasized by the Quality Standards
Subcommittee of theAmericanAcademyofNeurology; suggesting
the need for a coordinated approach to the care of WWE, with
interdisciplinary communication from primary care physicians,
obstetricians, geneticists and neurologists (AAN QSS 1998).
The National Institute of Clinical Excellence Clinical Practice
Guideline in the UK (Stokes 2004) recommends that the con-
tent of preconception counselling include review of diagnosis and
treatment with the aim of optimising seizure control and promot-
ing fertility, through offering advice on drug substitution or AED
withdrawal. Folic acid supplementation is recommended, com-
mencing during the preparatory phase (dosing advice and guide-
line recommendations varying bothwithin and between countries,
with doses between 0.4 mgs and 4 mgs recommended in the US,
while 5 mgs is recommended in the UK) (Kjaer 2007). The in-
formational content of preconception counselling should include
information on teratogenic effect of AEDs, effects of pregnancy
on seizure control, effects of epilepsy on the foetus, and the risk of
inheritance (Stokes 2004). Earlier guidelines included topics such
as contraception, birth and the neonatal period, breastfeeding and
care of the infant (ILAE 1993).
Measures of the effectiveness of preconception counselling would
be improvements in patient knowledge, and positive changes to
health promoting behaviours such as engagement with services to
improve seizure control, review of antiepileptic medication ahead
of conception, and commencement of folic acid, all with the goal
of reducing adverse pregnancy outcomes for mother and child.
This review will address these important issues affecting women
with epilepsy and their children.
O B J E C T I V E S
The primary objective of this review is to determine the effective-
ness of preconception counselling aimed at:
• reducing adverse pregnancy outcome in both mother
and child;
• increasing the knowledge of women with epilepsy;
• increasing intention to plan pregnancy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
(1) Randomised control trials; including quasi-randomised and
cluster randomised trials where the unit of randomisation is the
epilepsy clinic population (e.g. adolescent clinic).
(2) Prospective cohort studies.
(3) Controlled before and after studies.
(4) Interrupted time series.
Types of participants
The review includes studies of women of childbearing potential
(12 to 50 years) with a confirmed diagnosis of epilepsy (in the UK,
the diagnosis of epilepsy in adults should be established by a spe-
cialist medical practitioner with training and expertise in epilepsy)
(Stokes 2004). Women with epilepsy (WWE) for the purpose of
the review, includes any women diagnosed with epilepsy contin-
uing to take antiepileptic medication into childbearing age, and
any women with active epilepsy (one or more seizures in the last
two years) on or off treatment.
Types of interventions
Preconception counselling, defined as educational and counselling
interventions targeted at WWE prior to conception, with the in-
tention of reducing adverse pregnancy outcomes.
The range and content of the interventions were based on the
following sources; National Collaborating Centre for Primary
Care and National Institute of Clinical Excellence (NICE 2004;
Stokes 2004), Scottish Intercollegiate Guideline Network (SIGN
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2003), Recommended Best Practice forWWE preparing for Preg-
nancy (Crawford 1999);CommissiononGenetics, Pregnancy, and
the Child, International League Against Epilepsy (ILAE 1993);
Guidelines for the Care of WWE (Janz 1989; Morrell 1998); and
Consensus Guidelines (Delgado-Escueta 1992).
The intervention should include any activity (health education or
counselling activity) with the aim of reducing adverse pregnancy
outcome in WWE of child-bearing age.
Interventions might include, for example, any combination of the
following listed items.
• Review of epilepsy diagnosis.
• Discussion of the importance of planned pregnancy.
• Discussion of the potential interaction of AEDs and
hormonal contraception.
• Commencement of folic acid prior to conception.
• Discussion of the risk of malformation (major, minor
anomalies and dysmorphic features) in exposed infant.
• Discussion of the risk of cognitive delay in exposed in-
fant.
• Discussion of drug-specific pregnancy risk.
• Discussion of the importance of good seizure control
and medication compliance.
• Discussion of seizure risk (maternal and fetal).
• Review of AEDs (adjustment of number of AEDs,
switch from polytherapy to monotherapy, switch of
AEDs).
• Review of AED withdrawal in woman with epilepsy in
remission for > 2 years.
• Discussion of the potential benefits and limitations of
prenatal diagnostic testing achieved by booking early
into antenatal (perinatal) care.
• Discussion of safe child care, including advice on breast-
feeding.
• Registration of the pregnancy with an appropriate reg-
ister.
The comparison group should be WWE of childbearing age man-
aged with usual care, defined as no targeted educational or coun-
selling preconception intervention.
Types of outcome measures
Primary outcomes
Maternal outcomes
• Increased knowledge of pregnancy and treatment risk
(increase in knowledge measured by validated epilepsy
knowledge/quality of life scale. There are a number of
knowledge/quality of life scales that might be used; it is
recognised that the nature of increased knowledge will
be defined by the scale employed).
Fetal outcomes
• Reduced incidence of all major and minor congenital
malformation/anomaly, including reduced incidence of
developmental delay (as defined by trial authors).
Secondary Outcomes
Maternal outcomes
• Mortality (defined as death of a woman while pregnant
or up to 12 months after delivery as a result of pre-
existing epilepsy or onset of epilepsy during pregnancy,
and not due to direct obstetric causes). Indirect mater-
nal death related to epilepsy includes death classified as
SUDEP.
• Morbidity (increased seizure frequency or severity (mea-
sured by seizure severity index or scale), treatment side
effects, serious adverse events, postnatal depression).
• Reduction in number of unplanned pregnancies.
• Commencement of folic acid 5 mg daily.
• Increased concordance with epilepsy
treatment/management plan.
• Increased uptake of breastfeeding.
• Increased satisfaction with care.
• Adherence to intervention.
Fetal outcomes
• Reduced infant mortality.
• Reduced morbidity (reduced admission into Special
Care Baby Unit/Neonatal intensive care).
• Preterm birth (defined as the delivery of a baby before
37 completed weeks’ gestation).
• Small-for-gestational age (based onbirthweight, defined
as birthweight below the 10th percentile for gestational
age).
Timing of outcome assessment
• Measurement of change following intervention.
Economic data
• Cost-effectiveness analysis.
• Cost-utility analysis.
• Direct and indirect costs, both immediate and long-
term.
Search methods for identification of studies
We searched the Epilepsy Group’s Specialized Register (30 Jan-
uary 2008). This register contains reports of trials identified from
regular searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) and of MEDLINE. Relevant reports are also
identified by hand searching selected journals and conference pro-
ceedings. A more detailed description of this activity can be seen
by clicking on the link above.
In addition, we searched the following electronic databases up to
March 2008:
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(1) The Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library, Issue 4, 2007).
(2) Bibliographic databases, including MEDLINE (OVID)
(1950-February 2008); SCOPUS (1966-March 2008); CINAHL
(1982-March 2008); PsyclNFO (1806-March 2008); ASSIA
(1987-March 2008).
We did not impose language restrictions.
We used the following search strategies:
Electronic databases
MEDLINE (OVID)
1. epilep$.mp. [mp=title, original title, abstract, name of substance
word, subject heading word]
2. exp EPILEPSY/
3. seizure$.mp. [mp=title, original title, abstract, name of sub-
stance word, subject heading word]
4. exp SEIZURES/
5. 1 or 2 or 3 or 4
6. exp Preconception Care/
7. (prepregnancy or pre-pregnancy or “pre pregnancy”).mp.
[mp=title, original title, abstract, name of substance word, subject
heading word]
8. (plan$ adj3 pregnan$).ti,ab.
9. (plan$ adj3 conceive).ti,ab.
10. (plan$ adj3 conception).ti,ab.
11. (preconception$ or pre-conception$ or “pre conception”).mp.
[mp=title, original title, abstract, name of substance word, subject
heading word]
12. reproductive health.mp.
13. exp FAMILY-PLANNING
14. (family planning or planned parenthood).ti,ab.
15. exp FOLIC ACID/
16. exp Counseling/
17. (counsel$ or educat$ or inform$ or advice or advise).mp.
[mp=title, original title, abstract, name of substance word, subject
heading word]
18. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
19. 16 or 17
20. 18 and 19
21. 20 or 6
22. 5 and 21
We also searched the following databases using the modified ver-
sion of the above strategy:
• SCOPUS (1966-March 2008)
• CINAHL (1982-March 2008)
• PsyclNFO (1806-March 2008)
• ASSIA (1987-March 2008)
References from published studies
Other sources included:
• We handsearched Epilepsia, Epilepsy and Behavior,
British Journal of Obstetrics and Gynaecology, American
Journal of Obstetrics and Gynecology,Maternal and Child
Health Journal and conference abstracts and proceed-
ings for both national and international epilepsy and
obstetric meetings.
• We reviewed reference lists of all retrieved studies and
relevant reviews to search for additional reports of rele-
vant studies.
• We contacted authors of relevant papers and experts in
the field were contacted to identify any additional trials,
or unpublished work.
• We searched the Database of Abstracts of Reviews of
Effectiveness (DARE) was searched for related reviews
(June 2007).
Data collection and analysis
Selection of studies
JW carried out the searches, and read all the abstracts found to
identify publications that appeared to meet the inclusion criteria.
Each of the other review authors (AJ, RS & GB) independently
checked the search results and identified studies. All four review
authors independently read the identified studies, and classified
them as either:
(1) relevant (meeting all of the pre-specified inclusion criteria);
(2) possible (meeting some, but not all, inclusion criteria); and,
(3) rejected (not relevant to the review, failing to meet any of the
inclusion criteria).
All review authors examined full-text versions of all studies classi-
fied in categories (1) and (2). The final results were reached by con-
sensus amongst the review authors, with disagreements resolved
by discussion. We contacted the authors of the leading pregnancy
registers, and asked whether they were involved in or aware of any
additional studies assessing pre-pregnancy interventions (EURAP
2006; Holmes 2004; Morrow 2006). We contacted trial authors
for missing information and data.
Data extraction and management
Weplanned to use data extraction forms to gather data on study lo-
cation, methods, and participant characteristics at baseline, details
of the intervention and control group management and outcome.
It was agreed that two review authors would independently un-
dertake data abstraction, entering data into ReviewManager Soft-
ware (RevMan 2003). Disagreements would be resolved through
discussion by the two review authors. We would seek missing and
unclear data from the authors as necessary to perform the planned
analysis.
We planned to perform double-data entry.
Assessment of methodological quality of included studies
We planned to assess the quality of included studies according to
the following characteristics:
(1) allocation bias;
(2) performance bias;
(3) detection bias;
(4) report bias;
(5) attrition bias;
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(6) outcome validity.
We planned to assess the validity (the effect of design and conduct
on the risk of systematic error or bias) of included study using
the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2005).
Randomised control trials and cluster randomised control tri-
als
Weplanned to describe themethods used to generate the randomi-
sation sequence for randomised control trials to consider issues of
bias as follows:
(1) Selection bias (allocation concealment)
Assign a quality score for each trial, using the following criteria:
(a) adequate concealment of allocation: such as telephone ran-
domisation, consecutively numbered sealed opaque envelopes;
(b) unclear whether adequate concealment of allocation: such as
list or table used, sealed envelopes or study does not report any
concealment approach;
(c) inadequate concealment of allocation: such as open list of ran-
dom number tables, use of case record numbers, dates of birth or
days of the week.
(2) Attrition bias (loss of participants, e.g. withdrawals,
dropouts, protocol deviations)
Assess completeness to follow up using the following criteria:
(a) less than 5% loss of participants;
(b) 5% to 9.9% of loss of participants;
(c) 10% to 19.9% loss of participants;
(d) more than 20% loss of participants.
(3) Performance bias (blinding of participants, researchers and
outcome assessment)
Assess blinding using the following criteria:
(a) blinding of participants (yes/no/unclear);
(b) blinding of caregiver (yes/no/unclear);
(c) blinding of outcome assessment (yes/no/unclear).
Measures of treatment effect
We planned to carry out statistical analysis using the ReviewMan-
ager software (RevMan 2003), and to use fixed-effect meta-anal-
ysis to combine data in the absence of significant heterogeneity if
trials had been sufficiently similar. We planned to deal with het-
erogeneity if found, using sensitivity analysis followed by random-
effects analysis if required.
Dichotomous data
For dichotomous data, we planned to present the results as sum-
mary relative risk with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the weighted mean differ-
ence if outcomes were measured in the same way between trials.
We planned to use the standardised mean difference to combine
trials that measured the same outcome, but used different meth-
ods. We also planned to report evidence of skewness.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses,
along with individually randomised trials. We planned to adjust
their sample sizes using methods described by Gates 2005, us-
ing estimates of the intra-cluster correlation co-efficient (ICC) de-
rived from the trial (where possible), or from other sources. If
ICCs from other sources were used, we would report this, and
conduct sensitivity analyses to investigate the effect of variation in
the ICC. Where both cluster-randomised trials and individually
randomised trials were identified, we planned to synthesise the
relevant information and combine the results from both, if there
was little heterogeneity between study designs and interactions be-
tween the effect of the intervention and the choice of randomisa-
tion unit were considered unlikely.
We planned to acknowledge heterogeneity in the randomisation
unit and perform a separate meta-analysis.
Dealing with missing data
We planned to analyse data on all participants with available data
in the group to which they were allocated, regardless of whether
or not they received the allocated intervention. If in the original
reports participants were not analysed in the group to which they
were randomised, whilst sufficient information was in the trial
report, attempts would be made to restore them to the correct
group.
Assessment of heterogeneity
We planned to apply tests of heterogeneity between trials (chi-
squared test), if appropriate, quantifying inconsistency across stud-
ies using the I-squared (I²) statistic (Higgins 2005). If high levels of
heterogeneity were identified among the trials, (exceeding 50%),
we planned to explore them using a priori subgroup analysis and
sensitivity analysis. A random-effects meta-analysis was planned
as an overall summary if considered appropriate.
Dealing with multiple outcome data
For the purpose of statistical analysis of multiple comparisons be-
tween study groups/outcomes we planned to apply the Bonferroni
technique. This technique is appropriate to reduce error rate and
adjust for multiple dependent variables.
Subgroup analyses
We planned to conducted subgroup analyses as data permitted;
classifying whole trials by interaction tests as described by Deeks
2001; and, subgroup analyses of the primary outcomes:
• parity-primigravid versus parous women;
• number of counselling sessions - one session versusmore
than one;
• different types of counselling/communication delivery
styles;
• timing of intervention - as continual process of planned
preconception intervention, at timed intervals up to
conception (i.e. one year prior, six months prior)
Sensitivity analyses
We planned to evaluate sensitivity analysis exploring the effect of
trial quality assessed by concealment of allocation, and excluding
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studies with clearly inadequate allocation of concealment (rated
C).
Prospective cohort
We planned to use the Newcastle-Ottawa Scale to assess quality,
reporting on selection, comparability and outcome. In addition,
we planned to consider the following criteria adapted from Khan
2001.
(1) Were the groups comparable on all important confounding
factors?
(2) Was there adequate adjustment for the effects of these con-
founding variables?
(3) Was the intervention reliably ascertained?
(4) Was outcome assessment blind to intervention status?
(5) Was follow up long enough for the outcomes to occur?
(6)What proportion of the cohort/study group were followed up?
(7) Were drop-out rates and reasons for drop-out similar across
intervention and non-intervention group?
Controlled before and after studies (CBA)
We planned to apply the seven standard criteria developed by the
Cochrane EPOC Group to assess methodological quality.
(1) Baseline measurement:
• done, if patient or performance outcomes measured
prior to the intervention, and no substantial differences
were present across study groups (e.g. where multiple
pre-intervention measures describe similar trends in in-
tervention and control group(s).
(2) Characteristics of studies using second site as control:
• done, if characteristics of study and control providers
are reported and similar.
(3) Blinded assessment of primary outcome(s) with protection
against detection bias:
• done, if the authors state explicitly that the primary
outcome variables were assessed blindly OR the out-
come variables are objective (e.g. assessed by standard-
ised test).
(4) Protection against contamination in studies using a second site
as control:
• done, if allocation was by community, institution, or
practice and was unlikely the control group received the
intervention.
(5) Reliable primary outcome measure(s):
• done, if two or more raters with at least 90% agreement
or kappa greater than or equal to 0.8 OR the outcome
were obtained from some automated system (e.g. as-
sessed by standardised test).
(6) Follow-up of professionals (protection against exclusion bias)
• done, if outcome measures obtained 80-100% subjects
allocated to groups.
(g) Follow up of patients:
• done, if outcome measures obtained 80-100% of pa-
tients allocated to groups or for patients who entered
the study.
Interrupted time series (ITS)
We planned to use criteria developed by the Cochrane EPOC
Group to assess methodological quality.
We planned to include studies with ITS design only if they met
the following two criteria.
(1) Clearly defined point in time when the intervention occurred.
(2)At least three data points before and three after the intervention.
We planned to apply the following quality criteria for ITS design.
(1) Protection against secular changes:
• the intervention is dependent of other change.
(2) Data analysed appropriately:
• done, if Auto Regression Integrated Moving Average
models used OR times series regression models used to
analyse the data and serial correlation adjusted/tested
for;
• if there are sufficient data points to enable reliable sta-
tistical inference;
• done, if at least 20 data points recorded before the in-
tervention AND the authors had done traditional time
series analysis Model, OR at least three data points
recorded pre- and post-intervention AND the authors
had done a repeatedmeasure analysisOR if at least three
data points recorded pre and post intervention AND
the authors had used ANOVA or multiple t-tests AND
there were at least 30 observations per data point;
• formal test for trend, judged complete if authors used
ANOVA modelling.
(3) Reason for the number of points pre- and post-intervention
given:
• done, if rationale for the number of points stated (e.g.
monthly data for 12 months post-intervention used be-
cause anticipated effect expected to decay) OR sample
size calculation performed.
(4) Shape of the intervention effect specified:
• done, if rationale explanation for the shape of interven-
tion effect given by authors.
(5) Protection against detection bias:
• intervention unlikely to affect data collection;
• blinded assessment of primary outcome(s).
(6) Completeness of data set:
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• done, if data set covers 80-100% of total number of
participants.
(7) Reliable primary outcome measure(s):
• done, if two or more raters with at least 90% agreement
or Kappa greater than or equal to 0.8 OR the outcome
is obtained from some automated system assessed by a
standardised test.
R E S U L T S
Description of studies
See: Characteristics of excluded studies; Characteristics of ongoing
studies.
The search strategy generated 225 citations, of which two were
from the Cochrane Epilepsy Group Specialized Register. From the
initial search results, we discounted 211 papers as not relevant, of
which, 65 were guideline documents and narrative review articles,
including two systematic reviews of the effectiveness of precon-
ception counselling in a non-epilepsy population. Of note; from
those discounted, four surveyed the information needs of WWE,
six assessed the information needs of professionals/organisations.
Following retrieval for assessment, we discounted four articles as
not including WWE in their study population, and another eight
as non-interventional. We contacted 17 authors for additional in-
formation/data to enable appropriate assessment of eligibility.
We considered 11 studies (14 published papers) potentially rel-
evant and retrieved them for further assessment; from these, we
excluded five studies as they did not meet the inclusion criteria
for preconception intervention (Candito 2006; Candito 2007;
Czeizel 1999; Kampman 2005; Martin 1993). From this group,
the descriptions of intervention were variable: describing a sin-
gle intervention; pre-/peri-conception folic acid or multivitamin
supplementation (Candito 2006; Candito 2007; Czeizel 1999)
and AED drug change policy (Martin 1993). The Hungarian ran-
domised controlled trial by Czeizel 1999 measured the effect of
folic acid supplementation on pregnancy outcome, with long-term
outcomes assessed in a case-control trial.
Of the remaining six studies judged potentially relevant, the study
design included one before and after study (Oguni 1992) and five
retrospective case note reviews (Betts 1999; Cox 1992; Richmond
2004; Sablock 2002; Seale 1998). The review group discussed
each paper initially considered potentially relevant, reviewing the
merits of each. After much deliberation and discussion, we made
a final decision based on their relevance, using the predetermined
inclusion criteria, with no disagreements. No study met the inclu-
sion criteria; the rationales for exclusions are shown in the ‘Char-
acteristics of excluded studies’ table.
Contact with two authors identified an ongoing preconception
intervention study in Croatia (Miskov) and a reanalysis of data
from a cohort of preconception counselled women identified by
poor outcome in an earlier pregnancy (Mawer); these are displayed
in the ‘Characteristics of ongoing studies’ table.
We considered three studies potentially eligible. For two studies (
Beffa Negrini 1998; Shafer 1996) we have contacted their authors
to verify relevant information; both remain listed as ‘Studies await-
ing assessment’ (Beffa Negrini 1998 awaiting translation; Shafer
1996, awaiting author reply). For the third study Nguyen 2007)
we are awaiting translation.
Risk of bias in included studies
No studies met the eligibility criteria for inclusion in the review.
Effects of interventions
No studies met the eligibility criteria for inclusion in the review.
D I S C U S S I O N
We found no high-quality studies that addressed the effectiveness
of preconception counselling to optimise pregnancy outcome in
WWE. We located and appraised several studies that attempted
to show evidence of the positive effect of counselling interven-
tion. Although each of these studies reported on the outcome of
preconception intervention, we can draw no firm conclusions or
implications for practice because of the methodological weakness
of the studies.
Learning from the work conducted in this field of research demon-
strates the potential opportunities for conducting studies in this
population. The majority of studies identified as potentially rel-
evant were retrospective in design, making comparison of coun-
selled WWE to non-matched un-counselled pregnant WWE;
counselled women with other chronic diseases; or no comparison
group. Although we excluded these studies as not meeting the re-
view inclusion criteria, due to the risk of introducing bias, they
suggest positive benefit from preconception counselling interven-
tions. These examples demonstrate the methodological challenges
in trial design and the dependence on clearly defined interventions.
The complexity of the preconception intervention requires fur-
ther investigation to identify the components of the intervention
that are likely to be ’active’ to support their reproducibility within
a trial. This could be achieved by applying a framework, such as
that developed by the MRC, to develop and evaluate complex in-
terventions. The framework is based on developing a theoretical
underpinning by gaining insights into the interconnectedness of
the constituent parts of the intervention process, and acknowledg-
ing the multifaceted nature of the interventional components that
may act both independently and interdependently within a social
context (MRC 2000).
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Preconception care is based in the desire to improve child health,
adopted by the Department of Health in the concept “healthy
mothers produce healthy babies who become healthy children and
adults”(DH 2004). This concept is also espoused in the United
States, with the goal of improving preconception and reproductive
health outcomes, with the potential for reducing societal costs (
MMWR2006). The general concept of improvingwomen’s health
during their childbearing years has been transformed into precon-
ception health promotion activity for all women, promoting the
use of folic acid; reduction of smoking, alcohol and illicit drug use
prior to conception; and for women with chronic disease, the need
for additional disease/treatment specific care prior to conception.
We identified studies evaluating the delivery of preconception
counselling to the wider community of women with chronic dis-
eases during the review search strategy, and while not relevant to
this review, the potential to measure the effectiveness preconcep-
tion counselling for women with diabetes has been studied exten-
sively. The meta-analysis by Ray 2001 demonstrates a reduction
inmajor anomalies in pooled data from 14 cohorts ,showing fewer
anomalies in preconception care recipients than non-participants
(RR 0.36, 95%CI 0.22 to 0.59); and lowering of the risk of major
and minor anomalies in women who received preconception care
(RR 0.32, 95%CI 0.17 to 0.59). Of interest in relation to the
components of preconception care, they located only one study
that evaluated the addition of preconception folic acid to stabilis-
ing glycaemic control prior to conception, concluding that stud-
ies must include a range of interventions associated with improv-
ing pregnancy outcome, such as smoking cessation and folic acid
use, while drawing caution to generalising from their results (Ray
2001).
Comparison of effectiveness of preconception counselling drawn
from the study of counselling women with conditions including
diabetes mellitus, phenylketonuria, blood disorders, asthma and
hypothyroidism (to name but a few) may offer some support for
the timing and delivery of optimal preconception care, but it is
unclear whether direct comparisons can be made for WWE. Fur-
ther evaluation in the general population of women at risk of poor
pregnancy outcome has had variable success, with the RCT tar-
geting women at risk of low birth weight babies in Australia draw-
ing caution to the potential for detecting negative outcomes, an
outcome not envisaged at the trial design stage (Lumley 2006).
Following from this systematic review of preconception care for
WWE, it is evident further work is required to build theory and
model formajor confounders and identify underlyingmechanisms
to develop well-designed randomised controlled trials and cluster
randomised trials to address the safety and efficacy of preconcep-
tion counselling to reduce adverse pregnancy outcome in WWE.
Prospective cohort studies, interrupted time series and before and
after studies along with qualitative studies, are required to explore
and describe the components of preconception counselling and
the optimal delivery methods.
There remains a need to evaluate the cost-effectiveness of promot-
ing the general concept of preconception counselling in women’s
health care. By drawing on social marketing theories, a business
case can be proposed, pointing to the need for evidence of effec-
tiveness, defining the optimum methods of interventional deliv-
ery, and establishing how costs and benefits might be distributed
among the healthcare organisation (Grosse 2006). Future service
developments must take into account that less than half the target
population of WWE of childbearing potential plan pregnancy;
emphasizing the need to both promote and create a demand for
preconception care amongst WWE and their healthcare providers
(Prue 2006).
The review has demonstrated that whilst there is widespread sup-
port for pre-conception counselling interventions forWWE, there
is insufficient evidence to evaluate their effectiveness in this group,
thus preventing estimates of the likely benefit, harms or costs to
reduce adverse pregnancy outcome. The need remains for robust
evidence to support the provision of services for WWE during
their childbearing years. While there is uncertainty of effective-
ness, the component parts of the preconception intervention must
be evaluated to avoid the risk of increasing adverse outcome.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no information available from appropriately designed
studies to support the role of preconception counselling forWWE,
or identify which elements of counselling or mode of delivery
might be most effective.
Implications for research
We require well-designed, appropriately powered, randomised
controlled trials, prospective cohorts, controlled before and after
trials, and interrupted time series to evaluate the effectiveness of
preconception counselling.Whilewe judge randomised controlled
trials as offering the best evidence of interventional effectiveness,
we recognise that other study designs may be required to define,
identify and test the active components of the intervention as sug-
gested within the MRC framework. The following topics require
further investigation:
• What clinical and behavioural interventions provided
before pregnancy will improve pregnancy outcome for
WWE and their offspring?
• What is the effectiveness of the various components of
preconception counselling to reduce adverse pregnancy
outcome?
• How effective are different models of preconception
counselling delivery (including comparison of the role
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of healthcare professionals, settings and timings of de-
livery)?
• Howwould preconception counselling, delivered at dif-
ferent stages of a WWE’s reproductive life stages, influ-
ence pregnancy planning behaviour?
• What impact would preconception counselling have
upon quality of life and satisfaction of care?
• What impact would differing seizure severity have on
the outcome of preconception care and costs?
• What are the costs and benefits to the WWE and the
healthcare organisation?
In addition, qualitative research enquiry is needed to answer:
• How do WWE plan pregnancies?
• What do WWE want from preconception care?
We make the following suggestions for design and conduct of
future trials.
• Prospective evaluation of the outcome of preconception
counselling.
• Trials should be appropriately powered to rule out im-
portant differences in maternal and fetal outcome.
• Trials must look at clinically relevant outcomes, includ-
ing health outcomes for both WWE and infants of
mothers with epilepsy, satisfaction, resource utilisation
and costs should be measured using standardised meth-
ods.
• Trials need clearly specified inclusion criteria, including
definition of seizure frequency/control, AEDs efficacy
using validated scale.
• The provision of the intervention must be clearly spec-
ified, including: clearly defined role of the health pro-
fessional and WWE; the context of intervention deliv-
ery, including comparison of the effectiveness of non-
specialist intervention, primary care intervention, and
interventions offered opportunistically in family plan-
ning clinics.
• Data on economic outcomes including economic analy-
sis, to calculate costs, sensitive to the different resources
involved in preconception counselling used over the du-
ration of the episode(s) of care.
• Blinding of outcome assessment. While it might be dif-
ficult to blindWWE and clinicians to the intervention,
cluster randomised trials might overcome this obstacle.
It is necessary to blind outcome assessors to the inter-
vention group.
• Studies should be appropriately powered to enable the
long-term followup and outcome measurement.
• Consumer involvement at all stages of the trial, most
significant in the planning stage in order to identify
outcomes deemed of most relevance and importance.
• Trial protocols should be publicly available to allow
comparisonof reported outcomes andpre-specified out-
comes; and, allow reporting bias to be kept to a mini-
mum.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Betts 1999 Study design:
Retrospective case note review (Audit)
Participant:
WWE referred for preconception counselling (n = 85).
Pregnant WWE (control) no preconception counselling (n = 59).
Intervention:
Preconception investigation schedule, question and action point checklist, and preconception counselling check-
list.
Main findings:
No cases of MCM in counselledWWE, 11 cases in the control group (18%), with 3 terminations. Malformations
reported included spina bifida, congenital heart defect, hypospadias, microcephaly associated with developmental
delay, and skeletal deformity. Obstetric complications reported in 2 cases in counselled group (early miscarriage;
premature birth) and 3 cases in the control group (premature birth). All cases of MCM were linked to not
taking folic acid. Cases of malformation were associated with 45% of pregnant WWE taking two AEDs, whilst
sodium valproate, either alone or in combination, was associated with 64% of all malformations including those
terminated.
Reason for exclusion:
Retrospective study design. Additional data provided by author.
Candito 2006 Study design:
Case report.
Participant:
WWE receiving Lamotrigine during triplet pregnancy (n = 1). Controls: normal triplet pregnancy (n=1), normal
pregnant women with normal pregnancy (n = 58).
Intervention:
Pregnancy use of folic acid.
Main findings:
The results indicate a decrease in vitamin B12 and B6 values and polymorphism A66G in the patient.
Reasons for exclusion:
Case report design.
Candito 2007 Study design:
Case report.
Participants:
Cases: Pregnant WWE treated with Sodium Valproate (1500mgs total daily dose) and folic acid 5mg/day (n = 4),
Valproate controls: Pregnant WWE treated with the same dose of Sodium Valproate with normal pregnancies (n
= 2).
Controls without therapy: pregnant healthy women (n = 40).
Intervention:
Periconceptional 5mg/day folic acid supplementation
Main findings:
Potential for dysfunction in folate metabolism.
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(Continued)
Reasons for exclusion:
Case report design.
Additional data provided by author, awaiting response from second author.
Cox 1992 Study design:
Retrospective cohort.
Participants:
WWE and their partners preparing for pregnancy (n = 19).
Intervention:
Initial protocol assessment, detailed history, review of the partner, investigations, referral to a specialist were
necessary to plan care for future pregnancy.
Main findings:
Outcomes for WWEwere grouped with a wide range of chronic medical disorders (19/240); including, hyperten-
sion, diabetes mellitus, heart disease, renal disease, thyroid disease and asthma. This group all received counselling
and 63/240 attempted further pregnancy with 51(81%) having a live birth of a normal infant when compared to
their previous live birth rate 42% (95% CI difference 28.5-54.9%;x² test: P<0.001).
Reasons for exclusion:
Retrospective study design. No reply from author.
Czeizel 1999 Study design:
Randomised double blind placebo-controlled trial.
Participants:
Non-pregnant WWE (n = 60).
Healthy non-pregnant controls (n = 12 011).
Intervention:
1. Reproductive health check-up, detection of specific pregnancy risks.
2. 3 month preparation for pregnancy visit - risk assessment and management; intervention to reduce residual
risk, AND entry into RCT comparing supplementation with 0.8mg folic acid or no folic acid.
3. ’Benefit of periconceptional care’ visit, reinforcing benefits of folic acid & health promotion to ’protect early
pregnancy’.
4. Farewell visit at 10-12 wk gestation, referral to antenatal clinic.
Main findings:
The subset (’diabetes mellitus, cardiovascular diseases, epilepsy etc’) identified at first visit for specialist review, 8%
continued to treatment in pregnancy.
MCM = 1/60 in WWE not taking AEDs (cleft lip and palate).
No cases of ’epilepsy-related’ side effects in WWE.
One still birth in WWE (1/60) (taking CBZ 200mg daily and Clonazepam 3mg daily & preconception folic acid
0.8mg), experienced skin rash at 18wks gestation, seizures & status epilepticus secondary to additional vitamin
supplementation including 1mg folic acid.
Additional data on the outcome of WWE (n = 60) provided by author. No infant mortality or serious morbidity
until first birth year; rate of preterm birth (less than 37 week) in epilepsy group was 10% compared to 7.5% in
healthy controls (n = 8648); and rate of low birth weight (less than 2500g) was 15% in epilepsy group compared
to 4.4% in healthy controls.
Reasons for exclusion: The RCT compared supplementation with folic acid and preconceptual care was provided
to all study participants preventing assessment of effect in WWE.
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Kampman 2005 Study design:
Before and after study.
Participants:
215 electronic medical records of WWE.
28/215 pregnant WWE.
Intervention:
Passive guideline dissemination = publication of practice guidelines.
Active guideline dissemination = Interactive educational sessions for health professionals; patient educational
handouts; presentation of audit findings.
Main findings:
No MCM in active dissemination group; two infants were born with MCM (meningomyelocele, diagnosed
prenatally; biliary atresia, diagnosed postnatally) during the passive phase of guideline dissemination.
Fewer women took folic acid 0.4mg > 4 weeks before conception during active guideline dissemination (7/11
active compared to 15/17 passive), with no difference in higher dose folic acid 4mg use, recommended dose for
women taking Carbamazepine and Sodium Valproate > 4 weeks before conception (6/11 active compared to
10/17 passive). More women during the active guideline dissemination took the recommended dose of folic acid
during the first trimester (9/11 active compared to 9/17 passive).
Reasons for exclusion:
Intervention of interest not included.
Martin 1993 Study design:
Retrospective comparative cohort.
Participants:
Cohort 1 (1977-1981) 92 WWE with 118 pregnancies.
Cohort 2 (1987-1991) 115 WWE with 160 pregnancies. Compared to all registered pregnancies in Leicester
district for same time periods.
Intervention:
Changes in AED prescribing prior to second cohort.
Main findings:
MCM: 1st cohort 5/92(2.9%) (2.7% control); 2nd cohort 7/115 (4.8%)(4.1% control).
Perinatal deaths: 1st cohort 8/92 (4.7%)(1.4% control), 2nd cohort 3/115 (2.1%)(0.9% control).
Reasons for exclusion:
Retrospective study design, not including intervention of interest.
Attempts to contact authors were unsuccessful.
Oguni 1992 Study design:
Before and after study.
Participants:
Two cohorts of pregnant WWE.
Cohort 1 (1971-1984) (n = 94 reporting on 119 pregnancies).
Cohort 2 (1982-1989) (n = 103 reporting on 115 pregnancies).
Intervention:
Study aimed to detect changes in pregnancy outcome following the introduction of changes in prescribing practice.
Main findings:
Significant reduction in frequency of MCM (25.5% cohort 1 and 11.1% cohort 2, <0.01), attributed to changes
in prescribing. 68% of pregnancies exposed to monotherapy, compared to 40% prior to changes in practice.
Increase folic acid supplementation following changes in practice.
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Genetic predisposition to congenital malformations significantly higher in the comparison study population prior
to changes in practice ( < 0.01).
Reasons for exclusion:
The study was excluded as retrospective comparison group with no pre-intervention data.
Attempts to contact author unsuccessful.
Richmond 2004 Study design:
Retrospective case note review.
Participants:
WWE delivered between 1978-2000 (n = 414).
Intervention:
Preconception counselling delivered as routine care to all study population.
Main findings:
Outcome of MCM: WWE 26/414 (6.28%, p = 0.76) compared to non-epilepsy population (4.47%).
Reasons for exclusion:
Retrospective study design
Sablock 2002 Study design:
Retrospective case note review.
Participants:
Non-pregnant women with long-term medical disorders including 4/60 WWE.
Intervention:
Preconception counselling, review/withdrawal/changes of AEDs, secondary referral, commencement of folic acid.
Main findings:
The study authors concluded that few WWE were referred into the service in contrast with diabetes, suggesting
a lack of emphasis placed on preconception care by physicians who manage the care of WWE.
Reasons for exclusion:
Contact with author confirmed retrospective study design.
Seale 1998 Study design:
Retrospective chart review.
Participants:
Pregnant WWE delivered between 1988-1995 (n = 131; pregnancies, n = 161).
Intervention:
Preconception care provided as part of routine review with folic acid following practice guidelines. Preconception
care was provided by the obstetrician in 5%, and neurologist in 15% of pregnancies.
Main findings:
135 live births (84%), 26 cases of fetal loss before delivery, 6 fetal deaths and 5 neonatal deaths. Six infants
experienced intrauterine growth retardation; 3 resulting in death. MCM = 6. Folic acid supplementation increased
during the study period, with usage by AED treated women (n = 124) increasing from 68% (1988-1991), up to
78% (1992-1995).
Reasons for exclusion:
Retrospective study design.
WWE: Women with epilepsy
AED: Antiepileptic drug(s)
VPS: Sodium Valproate
CBZ: Carbamazepine
MCM: Major Congenital Malformation SE: Standard error
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Characteristics of ongoing studies [ordered by study ID]
Mawer
Trial name or title
Methods
Participants WWE recruited after poor outcome of earlier pregnancy.
Interventions Education and counselling.
AED switch or dose reduction.
Outcomes Measure change in frequency of MCM.
Starting date
Contact information George Mawer
Notes
Miskov
Trial name or title Surveillance of Croatian pregnant women with epilepsy - neurodevelopmental and teratogenetic effects of
antiepileptic drug exposure.
Methods Prospective trial.
Participants (1) WWE recruited before pregnancy.
(2) Pregnant WWE. 3) Healthy controls.
Interventions Intervention Group periconceptional folic acid; modification of AEDs (monotherapy instead of polytherapy,
switch of AED, monitoring of drug concentrations and changes of dosage).
Group 2&3- no preconception intervention.
Outcomes Measure: Planned versus unplanned pregnancy.
Variables - proportion of stillbirths, abortions, mode of delivery, preterm delivery, presence of MCM or
neurological delay & psychological status of child.
Starting date 2003
Contact information SnjeÅ¾ana Miškov MD PhD
Department of Neurology
University Hospital “Sisters of Mercy”
Vinogradska cesta 29, 10 000, Zegreb, Croatia
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Miskov (Continued)
Email: snjezana.miskov@zg.t-com.hr
Notes FU all children - neurological exam yearly until school age.
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 30 January 2008.
9 May 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 3, 2008
C O N T R I B U T I O N S O F A U T H O R S
J Winterbottom completed the bibliographic search, assessed methodological quality of all included studies, extracted data and wrote
the draft review. R Smyth, A Jacoby, G Baker reviewed search results, commented on study selection, assessed methodological quality
and commented on the review manuscripts.
D E C L A R A T I O N S O F I N T E R E S T
G Baker is the principal investigator for a study of the outcomes of pregnancy in WWE, which is partially funded by an educational
grant from Sanofi-Synthelabo.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• FO608 Epilepsy Research Foundation, UK.
During the time of preparing this review JanineWinterbottom was the recipient of a fellowship grant from Epilepsy Research
UK (ID: FO608).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects]; ∗Counseling; Epilepsy [∗drug therapy]; ∗Preconception Care; Pregnancy Outcome
MeSH check words
Female; Humans; Pregnancy
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